The Germany-based, Ammann and Staidson-backed inflammatory disease therapy developer has floated in an initial public offering in the US.
InflaRx, a Germany-based monoclonal antibody developer backed by pharmaceutical company Staidson and mechanical engineering group Ammann Group Holding, will raise $100m in its initial public offering after pricing its shares today.
The company will issue 6.67 million shares on the Nasdaq Global Select Market in the US, priced at $15.00 each, in the middle of the IPO’s $14 to $16 range.
InflaRx is developing treatments for autoimmune and other inflammatory diseases that will work by inhibiting an inflammatory mediator…
